Ajanta Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
May 02, 2024 at 04:40 pm IST
Share
Ajanta Pharma Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 10,540.8 million compared to INR 8,818.4 million a year ago. Revenue was INR 10,895.8 million compared to INR 9,186.7 million a year ago. Net income was INR 2,027.2 million compared to INR 1,222.5 million a year ago. Basic earnings per share from continuing operations was INR 16.1 compared to INR 9.54 a year ago. Diluted earnings per share from continuing operations was INR 16.09 compared to INR 9.54 a year ago.
For the full year, sales was INR 42,087.1 million compared to INR 37,426.4 million a year ago. Revenue was INR 42,933.1 million compared to INR 38,412.8 million a year ago. Net income was INR 8,161.7 million compared to INR 5,879.8 million a year ago. Basic earnings per share from continuing operations was INR 64.82 compared to INR 45.89 a year ago. Diluted earnings per share from continuing operations was INR 64.77 compared to INR 45.89 a year ago.
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.